We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) Raises Earnings & Sales Projections for Q4
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) communicated yesterday that its fourth-quarter 2019 results will likely be better than previously expected. The announcement was made by Thomas P. Joyce, Jr., the company’s president and chief executive officer, at a healthcare conference.
The news seems to have lifted market sentiments, contributing to yesterday’s share price increase of 1.14%. The trading session ended, with the share price at $161.39.
Inside the Headlines
As noted, healthy performances of the Life Sciences and Diagnostics segments will likely drive fourth-quarter 2019 organic sales growth above the previous expectation of 4.5%. Also, the company expects the quarter’s adjusted earnings per share to either meet or exceed the higher end of $1.32-$1.35 mentioned earlier.
Notably, the Life Sciences and Diagnostics segments generated roughly 65% of Danaher’s total revenues of $5,037.3 million in the third quarter of 2019.
The Zacks Consensus Estimate for fourth-quarter revenues and earnings are pegged at $5.28 billion and $1.25 per share, suggesting declines of 1.6% and 2.3% from the year-ago reported figures, respectively. Also, in the past 60 days, earnings estimates of $1.25 have been revised down by 6%.
Notably, Danaher will release fourth-quarter 2019 results before the market opens on Jan 30, 2020.
Zacks Rank, Earnings Estimate Trend and Price Performance
With a market capitalization of $114.6 billion, the company currently carries a Zacks Rank #3 (Hold). Over the past 60 days, the Zacks Consensus Estimate for earnings has decreased 3.8% to $4.57 for 2019 and 3% to $5.41 for 2020.
In the past 60 days, earnings estimates for these stocks have improved for the current year. Further, positive earnings surprise for the last four quarters, on average, was 17.67% for DXP Enterprises, 8.50% for Cintas and 4.01% for Chart Industries.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
Image: Bigstock
Danaher (DHR) Raises Earnings & Sales Projections for Q4
Danaher Corporation (DHR - Free Report) communicated yesterday that its fourth-quarter 2019 results will likely be better than previously expected. The announcement was made by Thomas P. Joyce, Jr., the company’s president and chief executive officer, at a healthcare conference.
The news seems to have lifted market sentiments, contributing to yesterday’s share price increase of 1.14%. The trading session ended, with the share price at $161.39.
Inside the Headlines
As noted, healthy performances of the Life Sciences and Diagnostics segments will likely drive fourth-quarter 2019 organic sales growth above the previous expectation of 4.5%. Also, the company expects the quarter’s adjusted earnings per share to either meet or exceed the higher end of $1.32-$1.35 mentioned earlier.
Notably, the Life Sciences and Diagnostics segments generated roughly 65% of Danaher’s total revenues of $5,037.3 million in the third quarter of 2019.
The Zacks Consensus Estimate for fourth-quarter revenues and earnings are pegged at $5.28 billion and $1.25 per share, suggesting declines of 1.6% and 2.3% from the year-ago reported figures, respectively. Also, in the past 60 days, earnings estimates of $1.25 have been revised down by 6%.
Notably, Danaher will release fourth-quarter 2019 results before the market opens on Jan 30, 2020.
Zacks Rank, Earnings Estimate Trend and Price Performance
With a market capitalization of $114.6 billion, the company currently carries a Zacks Rank #3 (Hold). Over the past 60 days, the Zacks Consensus Estimate for earnings has decreased 3.8% to $4.57 for 2019 and 3% to $5.41 for 2020.
Danaher Corporation Price and Consensus
Danaher Corporation price-consensus-chart | Danaher Corporation Quote
In the past three months, Danaher’s share price has increased 17.4% compared with the industry’s 15.3% growth.
Stocks to Consider
Some better-ranked stocks are DXP Enterprises, Inc (DXPE - Free Report) , Cintas Corporation (CTAS - Free Report) and Chart Industries, Inc (GTLS - Free Report) . While DXP Enterprises currently sports a Zacks Rank #1 (Strong Buy), Cintas and Chart Industries carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, earnings estimates for these stocks have improved for the current year. Further, positive earnings surprise for the last four quarters, on average, was 17.67% for DXP Enterprises, 8.50% for Cintas and 4.01% for Chart Industries.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
See their latest picks free >>